Asthmatx completes enrollment in pivotal study of bronchial thermoplasty

San Francisco, CA, May 21, 2007 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.

Leading asthma and bronchoscopy experts are participating in this international, multicenter AIR2 Trial to establish the safety and efficacy of the Alair System. Nearly 300 patients were enrolled in the study during the last 18 months at over 30 world-renowned medical centers including 15 US research hospitals. The AIR2 Trial is the fourth clinical study of the Alair Bronchial Thermoplasty System. To date, over 700 bronchoscopic procedures have been performed on asthma patients.

"We are very pleased to be a participant in this very important AIR2 Trial, the success of which will result in an important advancement in the treatment of severe asthma," states Mario Castro, MD, Associate Professor at the Washington University School of Medicine and Asthma Center, and a Principal Investigator in the AIR2 Trial. "As the lead enrolling center in the United States, we have experienced significant patient interest in bronchial thermoplasty, which we hope may become a new option for patients with difficult-to-treat asthma."

Final results of the first randomized and controlled clinical study of bronchial thermoplasty, the Asthma Intervention Research (AIR) Trial, were also reported today at the annual scientific assembly of the American Thoracic Society (ATS) by Gerard Cox, MB, Professor of Medicine, McMaster University, Canada, and principal investigato

Contact: Meghan Oreste

Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Approval to start US BTT pivotal trial
6. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
7. New data show CAS in clinical practice has comparable MAE rate with pivotal sapphire trial
8. Now is a pivotal point in history to abolish state execution
9. Orqis Medical receives unconditional FDA approval for pivotal trial of percutaneous CHF therapy
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. Penn study finds pro-death proteins required to regulate healthy immune function

Post Your Comments:

(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology:
Cached News: